Roivant Sciences/$ROIV
1D1W1MYTD1Y5YMAX
Capital at risk
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Ticker
- $ROIV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 721
- Headquarters
- London, United Kingdom
- Website
- roivant.com
Roivant Sciences Metrics
BasicAdvanced
$29B
-
-$0.49
1.13
-
Price and volume
Market cap
$29B
Beta
1.13
52-week high
$42.50
52-week low
$14.50
Average daily volume
8.9M
Financial strength
Current ratio
16.721
Quick ratio
13.624
Long term debt to equity
0.019
Total debt to equity
0.022
Profitability
EBITDA (TTM)
-1,358.516
Gross margin (TTM)
-9,610.89%
Net profit margin (TTM)
-3,534.96%
Operating margin (TTM)
-18,074.43%
Effective tax rate (TTM)
-43.03%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-16.46%
Return on equity (TTM)
-8.52%
Valuation
Price to revenue (TTM)
3,717.17
Price to book
6.8
Price to tangible book (TTM)
6.8
Price to free cash flow (TTM)
-34.099
Free cash flow yield (TTM)
-2.93%
Free cash flow per share (TTM)
-1.166
Growth
Revenue change (TTM)
-67.58%
Earnings per share change (TTM)
-29.49%
3-year revenue growth (CAGR)
-50.32%
3-year earnings per share growth (CAGR)
-28.56%
What the Analysts think about Roivant Sciences
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Analyst projections of the future price of Roivant Sciences stock.
Bulls say / Bears say
FDA approval of LISRAYA in dermatomyositis gives Roivant an immediately available commercial product and a differentiated position as the first and only targeted therapy approved for the disease; the VALOR trial showed meaningful improvements across disease activity and steroid reduction. (Roivant)
Roivant has several near-term clinical catalysts beyond LISRAYA, including late-stage brepocitinib programs, potentially registrational IMVT-1402 trials across multiple autoimmune diseases, and Phase 2 mosliciguat data in pulmonary hypertension associated with interstitial lung disease. (SEC)
Roivant remains heavily loss-making: first-quarter 2026 net loss was $290.6 million, while operating cash burn increased to $270.5 million from $204.4 million year over year as R&D and commercialization spending rose. (SEC)
The revenue base remains minimal and declined to $1.4 million in the first quarter of fiscal 2027 from $2.2 million a year earlier, underscoring the execution risk involved in converting LISRAYA’s approval into meaningful commercial sales. (SEC)
Roivant’s pipeline has already absorbed a setback with the discontinuation of batoclimab, leaving $42.5 million of non-cancelable contractual costs; additionally, LISRAYA carries boxed warnings covering serious infections, mortality, malignancy, major cardiovascular events and thrombosis, which could constrain adoption. (SEC; Roivant)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Roivant Sciences Financial Performance
Revenues and expenses
Roivant Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Roivant Sciences News
AllArticlesVideos
Funds containing Roivant Sciences
AllUSDGBPEUR
Fund name | Fund size | $ROIV weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.90% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.90% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.68% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.68% |
iShares Healthcare Innovation£DRDR | £1B | 1.68% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.